secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2023-06-30T23:59:59+00:00
Accession:  0001628280-23-024065
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland reports ifetroban well-tolerated with positive trend in DMD trial; no stat-sig
--------------------------------------------------------------------------------

- Interim analysis from 25 patients after 6 months; both ifetroban doses well-tolerated.
- Positive trend in leg muscle strength but no statistically significant differences at this early point.
- Phase II trial evaluating ifetroban for DMD cardiomyopathy; FDA awarded $1M orphan grant.
- Company plans to complete studies, analyze data, then decide development path for ifetroban registration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000162828023024065/0001628280-23-024065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000162828023024065/cpix-20230626.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-024065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer